| 1. |
- Hilson, P., et al.
(författare)
-
Versatile gene-specific sequence tags for Arabidopsis functional genomics : Trancript profiling and reverse genetics applications
- 2004
-
Ingår i: Genome Research. - : Cold Spring Harbor Laboratory. - 1088-9051 .- 1549-5469. ; 14:10B, s. 2176-2189
-
Tidskriftsartikel (refereegranskat)abstract
- Microarray transcript profiling and RNA interference are two new technologies crucial for large-scale gene function studies in multicellular eukaryotes. Both rely on sequence-specific hybridization between complementary nucleic acid strands, inciting us to create a collection of gene-specific sequence tags (GSTs) representing at least 21,500 Arabidopsis genes and which are compatible with both approaches. The GSTs were carefully selected to ensure that each of them shared no significant similarity with any other region in the Arabidopsis genome. They were synthesized by PCR amplification from genomic DNA. Spotted microarrays fabricated from the GSTs show good dynamic range, specificity, and sensitivity in transcript profiling experiments. The GSTs have also been transferred to bacterial plasmid vectors via recombinational cloning protocols. These cloned GSTs constitute the ideal starting point for a variety of functional approaches, including reverse genetics. We have subcloned GSTs on a large scale into vectors designed for gene silencing in plant cells. We show that in planta expression of GST hairpin RNA results in the expected phenotypes in silenced Arabidopsis lines. These versatile GST resources provide novel and powerful tools for functional genomics.
|
|
| 2. |
- El Daif, O., et al.
(författare)
-
Silver nanodiscs for light scattering in thin epitaxial silicon solar cells: Influence of the disc radius
- 2011
-
Ingår i: Materials Research Society Symposium Proceedings. - : Springer Science and Business Media LLC. - 0272-9172. - 9781627482110 ; 1391, s. 75-80
-
Konferensbidrag (refereegranskat)abstract
- The effect of silver nanoparticles showing localised plasmonic resonances on the efficiency of thin film silicon solar cells is studied. Silver (Ag) nanodiscs were deposited on the surface of silicon cells grown on highly doped silicon substrates, through hole-mask colloidal lithography, which is a low-cost and bottom-up technique. The cells have no back reflector in order to exclusively study the effect of the front surface on their properties. Cells with nanoparticles were compared with both bare silicon cells and cells with an antireflection coating. We optically observe a resonance showing an absorption increase controllable by the disc radius. We also see an increase in efficiency with respect to bare cells, but we see a decrease in efficiency with respect to cells with an antireflection coating due to losses at wavelengths below the plasmon resonance. As the material properties are not notably affected by the particles deposition, the loss mechanism is an important absorption in the nanoparticles. We confirm this by numerical simulations.
|
|
| 3. |
- Stenlöf, Kaj, 1965, et al.
(författare)
-
Effects of the microsomal triglyceride transfer protein (MTP) inhibitor JNJ-16269110 on glycemic control and body weight in subjects with type 2 diabetes mellitus (T2DM) on metformin
- 2010
-
Ingår i: Obesity Reviews (Poster presentations). - 1467-7881. ; 11:Supplement s1
-
Konferensbidrag (refereegranskat)abstract
- Introduction: JNJ-16269110 is a novel enterocyte-targeted MTP inhibitor acting via enterically-mediated hormonal and neural mechanisms being investigated for treatment of obesity. Methods: Three hundred and fifty two subjects with T2DM (BMI 32.8 kg/m2; 54% males) were randomized to placebo, JNJ-16269110 5-mg bid, 10-mg bid or 15-mg bid for 12 weeks in a double-blind multicenter clinical trial to assess safety and efficacy of this agent. The primary efficacy endpoint was change from baseline to Week 12 in HbA1c (ITT-mixed-model). Secondary endpoints included changes in fasting plasma glucose (FPG), body weight (BW), and plasma lipids. Results: Gastrointestinal symptoms were the most common reason for early discontinuation in the JNJ-16269110 arms (2%, 12%, 9% of subjects in 5-mg, 10-mg, 15-mg bid groups, respectively, vs. 1% in placebo group). Conclusion: Compared to placebo, JNJ-16269110 10-mg and 15-mg bid improved glycemic control and reduced BW. The most common side effects were related to the astrointestinal system. Conflict of interest: K. Stenlof received funding from Johnson and Johnson as principal investigator and consultant. E. Wajs, F. Vercruysse, D. Ways, S. Ouwerkerk-Mahadevan, J. Penson, and L. Van Nueten are employees and shareholders of Johnson and Johnson. Funding: The study was funded by Johnson & Johnson Pharmaceutical Research and Development.
|
|
| 4. |
- Stenlöf, Kaj, 1965, et al.
(författare)
-
Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
- 2007
-
Ingår i: Diabetes, obesity & metabolism. - : Wiley. - 1462-8902 .- 1463-1326. ; 9:3, s. 360-8
-
Tidskriftsartikel (refereegranskat)abstract
- AIM: The aim of this study was to examine the efficacy and safety of topiramate as an adjunct to diet and exercise in drug-naive, obese subjects with type 2 diabetes. METHODS: Drug-naive individuals with type 2 diabetes, body mass index (BMI) of > or =27 and <50 kg/m(2) and haemoglobin A(1c) (HbA(1c)) of <10.5% were enrolled into the study. All the individuals participated in a non-pharmacologic weight loss program (Pathways to Change((R)); Johnson & Johnson Healthcare Systems, Piscataway, NJ, USA) throughout the trial. After a 6-week placebo run-in, the subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Subjects were scheduled for 8-week titration and 52-week maintenance phases. The study was ended early; efficacy data were reported for a predefined modified intent-to-treat (MITT) population (n = 229), with 40 weeks of treatment. All the subjects who provided any safety data were included in the safety population (n = 535). RESULTS: Baseline mean weight was 103.7 kg, BMI 36 kg/m(2) and HbA(1c) 6.7% across all treatment groups. By the end of week 40, the placebo, the topiramate 96 mg/day and topiramate 192 mg/day groups lost 2.5, 6.6 and 9.1% of their baseline body weight respectively (p < 0.001 vs. placebo, MITT population using last observation carried forward). The decrease in HbA(1c) was 0.2, 0.6 and 0.7% respectively (p < 0.001 vs. placebo, MITT). Topiramate significantly reduced blood pressure and urinary albumin excretion; a weight-loss-independent HbA(1c) improving effect of topiramate was demonstrated. Adverse events were predominantly related to central nervous system (CNS). CONCLUSIONS: Topiramate as an add-on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug-naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS.
|
|
